Convolutional Neural Networks Enable Highly Accurate and Automated Subvisible Particulate Classification of Biopharmaceuticals

被引:0
作者
Shubing Wang
Andy Liaw
Yue-Ming Chen
Yongchao Su
Daniel Skomski
机构
[1] Merck & Co. Inc.,Department of Biometrics Research
[2] Merck & Co. Inc.,Analytical Research and Development
来源
Pharmaceutical Research | 2023年 / 40卷
关键词
biologics; characterization; machine learning; neural networks; subvisible particles;
D O I
暂无
中图分类号
学科分类号
摘要
Quantification of subvisible particles, which are generally defined as those ranging in size from 2 to 100 µm, is important as critical characteristics for biopharmaceutical formulation development. Micro Flow Imaging (MFI) provides quantifiable morphological parameters to study both the size and type of subvisible particles, including proteinaceous particles as well as non-proteinaceous features incl. silicone oil droplets, air bubble droplets, etc., thus enabling quantitative and categorical particle attribute reporting for quality control. However, limitations in routine MFI image analysis can hinder accurate subvisible particle classification. In this work, we custom-built a subvisible particle-aware Convolutional Neural Network, SVNet, which has a very small computational footprint, and achieves comparable performance to prior state-of-art image classification models. SVNet significantly improves upon current standard operating procedures for subvisible particulate assessments as confirmed by thorough real-world validation studies.
引用
收藏
页码:1447 / 1457
页数:10
相关论文
共 163 条
  • [1] Zolls S(2012)Particles in therapeutic protein formulations, Part 1: Overview of analytical methods J Pharm Sci 101 914-935
  • [2] Tantipolphan R(2020)Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge Adv Drug Deliver Rev 167 66-77
  • [3] Wiggenhorn M(2015)Subvisible (2–100 mu m) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis Biologicals 43 457-473
  • [4] Winter G(2015)Subvisible (2–100 mu m) particle analysis during biotherapeutic drug product development: part 1, considerations and strategy J Pharm Sci 104 1899-1908
  • [5] Jiskoot W(2009)Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality J Pharm Sci 98 1201-1205
  • [6] Friess W(2010)An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics J Pharm Sci 99 3302-3321
  • [7] Hawe A(2021)Surfactant impact on interfacial protein aggregation and utilization of surface tension to predict surfactant requirements for biological formulations Mol Pharm 18 148-157
  • [8] Sanchez-Felix M(2012)Issues and challenges of subvisible and submicron particulate analysis in protein solutions Aaps J 14 236-243
  • [9] Burke M(2018)Deep convolutional neural network analysis of flow imaging microscopy data to classify subvisible particles in protein formulations J Pharm Sci 107 999-1008
  • [10] Chen HH(2010)Characterization of particles in protein solutions: reaching the limits of current technologies Aaps J 12 708-715